BARDA exercised a $97 million option under its current contract with Bavarian Nordic to supply freeze-dried JYNNEOS smallpox vaccine doses. The award is a positive commercial development for the vaccine maker and supports backlog visibility, though it is unlikely to materially move the broader market.
BARDA exercised a $97 million option under its current contract with Bavarian Nordic to supply freeze-dried JYNNEOS smallpox vaccine doses. The award is a positive commercial development for the vaccine maker and supports backlog visibility, though it is unlikely to materially move the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.40
